TrialLancet (London, England)2021

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

Raches Ella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.